Currently Akt (MK2206) and mTOR (Temsirolimus) inhibitors are being evaluated in clinical trials for patients with various forms of cancer including prostate cancer (NCT01480154, 00919035). This evidence concerns the gene AKT1 and prostate carcinoma.